Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Savara (SVRA)
:SVRA
Holding SVRA?
Track your performance easily
SVRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.60 - $5.70
Previous CloseN/A
Volume189.20K
Average Volume (3M)1.15M
Market Cap
$499.41M
Enterprise Value$705.50M
Total Cash (Recent Filing)$13.37M
Total Debt (Recent Filing)$4.03M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Mar 13, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding171,618,940
10 Day Avg. Volume1,013,224
30 Day Avg. Volume1,154,093
Standard Deviation0.18
R-Squared0.04
Alpha0.00136
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.40
Forecast
1Y Price Target
$8.58Price Target Upside194.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Savara News
PremiumCompany Announcements
Savara Highlights MOLBREEVI’s Potential in Rare Disease Market
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageDurability of Molbreevi peak sales is enhanced by the low likelihood of competition from both branded and biosimilar drugs in ultrarare indications.
Market PotentialThe identification of approximately 1,000 diagnosed aPAP patients in the US before launch largely derisks near-term sales numbers.
Regulatory ApprovalThere is a 90%+ confidence in Molbreevi's regulatory approval for aPAP, as recent Phase III data suggests benefits on lung function and patient symptoms.
Bears Say
Market Opportunity And Growth ConcernsThere is not sufficient evidence to justify a $500M US market opportunity for Molbreevi.
Physician Engagement And Testing ChallengesThere seems to be some reluctance among physicians regarding patient testing, which is concerning since one of Savara's main strategies is targeting physicians and increasing testing.
Regulatory And Manufacturing RisksThe biggest risk to approval is manufacturing, as the current partner GEMA has never had a FDA approved product.
---
Ownership Overview
12.60% Insiders
10.66% Mutual Funds
0.02% Other Institutional Investors
66.88% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SVRA FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was $2.60 and its highest was $5.70 in the past 12 months.
What is Savara’s market cap?
Savara’s market cap is $499.41M.
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is Mar 13, 2025 which is in 54 days.
How were Savara’s earnings last quarter?
Savara released its earnings results on Nov 12, 2024. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.109 by -$0.001.
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -0.11.
How many shares outstanding does Savara have?
Savara has 171,618,940 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Savara reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.109. Following the earnings report the stock price went down -5.897%.
Which hedge fund is a major shareholder of Savara?
Currently, no hedge funds are holding shares in SVRA
---
Savara Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.58 (194.85% Upside)
$8.58 (194.85% Upside)
Blogger Sentiment
Bullish
SVRA Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 9.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $319.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.56%
12-Months-Change
Fundamentals
Return on Equity
-47.95%
Trailing 12-Months
Asset Growth
31.17%
Trailing 12-Months
Company Description
Savara
Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
---
SVRA Stock 12 Month Forecast
Average Price Target
$8.58
▲(194.85% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
BioCryst
―
Cerus
―
Kala Pharmaceuticals
―
Mersana Therapeutics
―
Best Analysts Covering SVRA
1 Year
1 Year Success Rate
5/13 ratings generated profit
1 Year Average Return
+3.09%
assigned a buy rating 3 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of +3.09% per trade.
---